Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17162692 | 1.00 | P2RX7 (0.38) | P2RX7MAPK1UCHL1ALDH1A1KMT2A | |
| SCHEMBL22688357 | 0.89 | P2RX7 (0.35) | P2RX7MAPK1ALDH1A1KMT2AOPRM1 | |
| SCHEMBL17178005 | 0.89 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL17177887 | 0.89 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL17178006 | 0.89 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL17174477 | 0.85 | DDB1 (0.38) | MAPK1ALDH1A1 | |
| SCHEMBL17174481 | 0.85 | DDB1 (0.38) | MAPK1ALDH1A1 | |
| SCHEMBL17162572 | 0.85 | DDB1 (0.38) | MAPK1ALDH1A1 | |
| SCHEMBL19149085 | 0.84 | P2RX7 (0.42) | P2RX7MAPK1 | |
| SCHEMBL17174472 | 0.84 | P2RX7 (0.42) | P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | P2RX7 3047/4885MAPK1 2233/4885UCHL1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.